首页> 外文期刊>The Journal of biological chemistry >Crystal Structure and Pharmacological Characterization of a Novel N-Methyl-d-aspartate (NMDA) Receptor Antagonist at the GluN1 Glycine Binding Site
【24h】

Crystal Structure and Pharmacological Characterization of a Novel N-Methyl-d-aspartate (NMDA) Receptor Antagonist at the GluN1 Glycine Binding Site

机译:新型N-甲基-D-天冬氨酸(NMDA)受体拮抗剂在GLUN1甘氨酸结合位点上的晶体结构和药理表征

获取原文
           

摘要

NMDA receptors are ligand-gated ion channels that mediate excitatory neurotransmission in the brain. They are tetrameric complexes composed of glycine-binding GluN1 and GluN3 subunits together with glutamate-binding GluN2 subunits. Subunit-selective antagonists that discriminate between the glycine sites of GluN1 and GluN3 subunits would be valuable pharmacological tools for studies on the function and physiological roles of NMDA receptor subtypes. In a virtual screening for antagonists that exploit differences in the orthosteric binding site of GluN1 and GluN3 subunits, we identified a novel glycine site antagonist, 1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one (TK40). Here, we show by Schild analysis that TK40 is a potent competitive antagonist with Kb values of 21–63 nm at the GluN1 glycine-binding site of the four recombinant GluN1/N2A-D receptors. In addition, TK40 displayed >100-fold selectivity for GluN1/N2 NMDA receptors over GluN3A- and GluN3B-containing NMDA receptors and no appreciable effects at AMPA receptors. Binding experiments on rat brain membranes and the purified GluN1 ligand-binding domain using glycine site GluN1 radioligands further confirmed the competitive interaction and high potency. To delineate the binding mechanism, we have solved the crystal structure of the GluN1 ligand-binding domain in complex with TK40 and show that TK40 binds to the orthosteric binding site of the GluN1 subunit with a binding mode that was also predicted by virtual screening. Furthermore, the structure reveals that the imino acetamido group of TK40 acts as an α-amino acid bioisostere, which could be of importance in bioisosteric replacement strategies for future ligand design.
机译:NMDA受体是配体门控离子通道,用于介导大脑中的兴奋性神经递血。它们是由甘氨酸结合的Glun1和Glun3亚基组成的四聚体复合物以及谷氨酸结合的Glun2亚基。亚单位选择性拮抗剂,鉴别Glun1和Glun3亚基的甘氨酸位点之间的有价值的药理学工具,用于研究NMDA受体亚型的功能和生理作用。在对拮抗剂的虚拟筛查中,用于剥削Glun1和Glun3亚基的正向结合位点的差异,我们鉴定了一种新型甘氨酸位点拮抗剂,1-硫代-1,2-二氢 - [1,2,4]三唑唑[4,3 -A]喹喔啉-4(5H) - ONE(TK40)。在这里,我们通过SCHILD分析显示TK40是一种有效的竞争性拮抗剂,在四个重组GLUN1 / N2A-D受体的GLUN1甘氨酸结合位点处具有21-63nm的KB值。此外,TK40显示> 100倍的GLUN1 / N2 NMDA受体对含有GLUN3A和GLUN3B的NMDA受体的选择性,并且在AMPA受体没有明显的影响。使用甘氨酸位点GLUN1放射性配体对大鼠脑膜和纯化的GLUN1配体结合结构域的结合实验进一步证实了竞争性相互作用和高效力。为了描绘粘合机制,我们已经用TK40解决了Glun1配体结合结构域的晶体结构,并显示TK40与粘合模式结合的GLUN1亚基的正末端结合位点,其也通过虚拟筛选预测的结合模式。此外,该结构表明,TK40的亚氨基乙酰氨基基团作用为α-氨基酸生物偏见,这可能对未来配体设计的生物脑药替换策略具有重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号